AB Science communique une mise à jour sur le calendrier des résultats cliniques
October 10, 2019 02:03 ET
|
AB Science
Paris, 10 octobre 2019, 8h AB Science communique une mise à jour sur le calendrier des résultats cliniques Annonce des résultats dans l’asthme et dans la sclérose en plaques confirmée au T4 2019 AB...
AB Science to present at two upcoming conferences in September 2019, the NewsMakers 2019 Healthcare conference and the H.C. Wainwright Healthcare Conference
August 12, 2019 13:08 ET
|
AB Science
Paris, August 12th,2019, 7pm AB Science to present at two upcoming conferences in September 2019, the NewsMakers 2019 Healthcare conference and the H.C. Wainwright Healthcare Conference AB Science...
AB Science fait le point sur le programme clinique du masitinib
August 05, 2019 01:31 ET
|
AB Science
Paris, 5 août 2019, 7h30 Point sur le programme clinique du masitinib AB Science SA (NYSE Euronext - FR0010557264 - AB) fait le point sur le programme clinique du masitinib. Les points...
AB Science provides an update on its masitinib clinical program
August 05, 2019 01:31 ET
|
AB Science
Paris, August 5 2019, 7.30am Update on masitinib clinical program AB Science SA (NYSE Euronext - FR0010557264 - AB) provides an update on its masitinib clinical program. The key points of...
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors
July 19, 2019 11:15 ET
|
Retrotope
LOS ALTOS, Calif., July 19, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it closed a Series C financing, enabling expansion of its pipeline of novel first-in-class drugs called D-PUFAs...
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
May 06, 2019 12:57 ET
|
Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)
March 13, 2019 13:23 ET
|
Retrotope
LOS ALTOS, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Retrotope received notification from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) that its request for...
Dr. Paul Carney Joins Biotica Pharmaceuticals as Neurologist Consultant and Scientific Advisor
January 03, 2018 08:00 ET
|
Biotica Pharmaceuticals Inc.
Sarasota, FL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Biotica Pharmaceuticals Inc. (Biotica), an early-stage biotech engaging in the discovery, development, and commercialization of cannabinoid-based...
Elsevier Recognizes Alzheimer's - Brain Awareness Month with New Book, "A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease"
June 06, 2017 04:00 ET
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - June 06, 2017) - Elsevier, the information analytics company specializing in science and health, today announced A Roadmap for Curing Cancer, Alzheimer's, and...
DiamiR Announces Oral Presentation at 2016 Alzheimer's Association International Conference
July 21, 2016 08:30 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ --(Marketwired - July 21, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today that the...